These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20215584)

  • 1. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases.
    Floettmann E; Gregory L; Teague J; Myatt J; Hammond C; Poucher SM; Jones HB
    Toxicol Pathol; 2010 Apr; 38(3):393-401. PubMed ID: 20215584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ; Greenhaff PL; MacInnes A; Timmons JA
    Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of streptozotocin-induced and obese diabetic rats.
    Docsa T; Czifrák K; Hüse C; Somsák L; Gergely P
    Mol Med Rep; 2011; 4(3):477-81. PubMed ID: 21468595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354. II. Anti-hyperglycemic effects in diabetic animal models.
    Furukawa S; Murakami K; Nishikawa M; Nakayama O; Hino M
    J Antibiot (Tokyo); 2005 Aug; 58(8):503-6. PubMed ID: 16266121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen phosphorylase inhibitors.
    Henke BR; Sparks SM
    Mini Rev Med Chem; 2006 Aug; 6(8):845-57. PubMed ID: 16918491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model.
    Sickmann HM; Waagepetersen HS; Schousboe A; Benie AJ; Bouman SD
    Neurochem Int; 2012 Feb; 60(3):267-75. PubMed ID: 22244844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hyperglycemia on hepatic gluconeogenic flux during glycogen phosphorylase inhibition in the conscious dog.
    Edgerton DS; Cardin S; Neal D; Farmer B; Lautz M; Pan C; Cherrington AD
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E510-22. PubMed ID: 14644767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
    van Poelje PD; Potter SC; Chandramouli VC; Landau BR; Dang Q; Erion MD
    Diabetes; 2006 Jun; 55(6):1747-54. PubMed ID: 16731838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentration.
    Taguchi T; Yamashita E; Mizutani T; Nakajima H; Yabuuchi M; Asano N; Miwa I
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E534-40. PubMed ID: 15536204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D; Kónya B; Chajistamatiou AS; Chrysina ED; Leroy J; Balzarin S; Tournier M; Tousch D; Petit P; Duret C; Maurel P; Somsák L; Docsa T; Gergely P; Praly JP; Azay-Milhau J; Vidal S
    Eur J Med Chem; 2016 Jan; 108():444-454. PubMed ID: 26708111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme.
    Freeman S; Bartlett JB; Convey G; Hardern I; Teague JL; Loxham SJ; Allen JM; Poucher SM; Charles AD
    Br J Pharmacol; 2006 Nov; 149(6):775-85. PubMed ID: 17016495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rapid onset of hyperglycaemia in ZDF rats was associated with a widespread alteration of metabolic proteins implicated in glucose metabolism in the heart.
    Lajoie C; Béliveau L; Trudeau F; Lavoie N; Massicotte G; Gagnon S; Calderone A
    Can J Physiol Pharmacol; 2006 Nov; 84(11):1205-13. PubMed ID: 17218985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats.
    Fujimoto Y; Torres TP; Donahue EP; Shiota M
    Diabetes; 2006 Sep; 55(9):2479-90. PubMed ID: 16936196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing mechanisms of hepatic glucose overproduction in triiodothyronine-treated rats vs. Zucker diabetic fatty rats by NMR analysis of plasma glucose.
    Jin ES; Burgess SC; Merritt ME; Sherry AD; Malloy CR
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E654-62. PubMed ID: 15562253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
    Yoshida T; Okuno A; Izumi M; Takahashi K; Hagisawa Y; Ohsumi J; Fujiwara T
    Eur J Pharmacol; 2008 Dec; 601(1-3):192-7. PubMed ID: 19014931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation: the role of mu-calpain.
    Scalia R; Gong Y; Berzins B; Zhao LJ; Sharma K
    Diabetes; 2007 Jul; 56(7):1842-9. PubMed ID: 17446533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon challenge in the rat: a robust method for the in vivo assessment of Glycogen phosphorlyase inhibitor efficacy.
    Loxham SJ; Teague J; Poucher SM; De Schoolmeester J; Turnbull AV; Carey F
    J Pharmacol Toxicol Methods; 2007; 55(1):71-7. PubMed ID: 16713718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hepatic targets for glycaemic control in diabetes.
    Agius L
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):587-605. PubMed ID: 18054737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA; Banker P; Bickett DM; Boucheron JA; Carter HL; Clancy DC; Cooper JP; Dickerson SH; Garrido DM; Nolte RT; Peat AJ; Sheckler LR; Sparks SM; Tavares FX; Wang L; Wang TY; Weiel JE
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1177-82. PubMed ID: 19138846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.